Simple view
Full metadata view
Authors
Statistics
1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis
1,4-dimethylpyridinium chloride
1-methylnicotinaimide chloride
angiogenesis
breast cancer
combined therapy
metastasis
Background: 1-methylnicotinamide (1-MNA), an endogenous metabolite of nicotinamide, has recently gained interest due to its anti-inflammatory and anti-thrombotic activities linked to the COX-2/PGI2 pathway. Given the previously reported anti-metastatic activity of prostacyclin (PGI2), we aimed to assess the effects of 1-MNA and its structurally related analog, 1,4-dimethylpyridine (1,4-DMP), in the prevention of cancer metastasis. Methods: All the studies on the anti-tumor and anti-metastatic activity of 1-MNA and 1,4-DMP were conducted using the model of murine mammary gland cancer (4T1) transplanted either orthotopically or intravenously into female BALB/c mouse. Additionally, the effect of the investigated molecules on cancer cell-induced angiogenesis was estimated using the matrigel plug assay utilizing 4T1 cells as a source of pro-angiogenic factors. Results: Neither 1-MNA nor 1,4-DMP, when given in a monotherapy of metastatic cancer, influenced the growth of 4T1 primary tumors transplanted orthotopically; however, both compounds tended to inhibit 4T1 metastases formation in lungs of mice that were orthotopically or intravenously inoculated with 4T1 or 4T1-luc2-tdTomato cells, respectively. Additionally, while 1-MNA enhanced tumor vasculature formation and markedly increased PGI2 generation, 1,4-DMP did not have such an effect. The anti-metastatic activity of 1-MNA and 1,4-DMP was further confirmed when both agents were applied with a cytostatic drug in a combined treatment of 4T1 murine mammary gland cancer what resulted in up to 80 % diminution of lung metastases formation. Conclusions: The results of the studies presented below indicate that 1-MNA and its structural analog 1,4-DMP prevent metastasis and might be beneficially implemented into the treatment of metastatic breast cancer to ensure a comprehensive strategy of metastasis control.
cris.lastimport.scopus | 2024-04-07T17:15:06Z | |
cris.lastimport.wos | 2024-04-10T00:19:04Z | |
dc.abstract.en | Background: 1-methylnicotinamide (1-MNA), an endogenous metabolite of nicotinamide, has recently gained interest due to its anti-inflammatory and anti-thrombotic activities linked to the COX-2/PGI2 pathway. Given the previously reported anti-metastatic activity of prostacyclin (PGI2), we aimed to assess the effects of 1-MNA and its structurally related analog, 1,4-dimethylpyridine (1,4-DMP), in the prevention of cancer metastasis. Methods: All the studies on the anti-tumor and anti-metastatic activity of 1-MNA and 1,4-DMP were conducted using the model of murine mammary gland cancer (4T1) transplanted either orthotopically or intravenously into female BALB/c mouse. Additionally, the effect of the investigated molecules on cancer cell-induced angiogenesis was estimated using the matrigel plug assay utilizing 4T1 cells as a source of pro-angiogenic factors. Results: Neither 1-MNA nor 1,4-DMP, when given in a monotherapy of metastatic cancer, influenced the growth of 4T1 primary tumors transplanted orthotopically; however, both compounds tended to inhibit 4T1 metastases formation in lungs of mice that were orthotopically or intravenously inoculated with 4T1 or 4T1-luc2-tdTomato cells, respectively. Additionally, while 1-MNA enhanced tumor vasculature formation and markedly increased PGI2 generation, 1,4-DMP did not have such an effect. The anti-metastatic activity of 1-MNA and 1,4-DMP was further confirmed when both agents were applied with a cytostatic drug in a combined treatment of 4T1 murine mammary gland cancer what resulted in up to 80 % diminution of lung metastases formation. Conclusions: The results of the studies presented below indicate that 1-MNA and its structural analog 1,4-DMP prevent metastasis and might be beneficially implemented into the treatment of metastatic breast cancer to ensure a comprehensive strategy of metastasis control. | pl |
dc.affiliation | Pion Rektora : Jagiellońskie Centrum Rozwoju Leków | pl |
dc.cm.id | 78854 | |
dc.contributor.author | Blazejczyk, Agnieszka | pl |
dc.contributor.author | Switalska, Marta | pl |
dc.contributor.author | Chłopicki, Stefan - 128995 | pl |
dc.contributor.author | Marcinek, Andrzej | pl |
dc.contributor.author | Gebicki, Jerzy | pl |
dc.contributor.author | Nowak, Marcin | pl |
dc.contributor.author | Nasulewicz-Goldeman, Anna | pl |
dc.contributor.author | Wietrzyk, Joanna | pl |
dc.date.accessioned | 2016-08-30T07:08:20Z | |
dc.date.available | 2016-08-30T07:08:20Z | |
dc.date.issued | 2016 | pl |
dc.date.openaccess | 0 | |
dc.description.accesstime | w momencie opublikowania | |
dc.description.points | 35 | pl |
dc.description.version | ostateczna wersja wydawcy | |
dc.description.volume | 35 | pl |
dc.identifier.articleid | 110 | pl |
dc.identifier.doi | 10.1186/s13046-016-0389-9 | pl |
dc.identifier.eissn | 1756-9966 | pl |
dc.identifier.issn | 0392-9078 | pl |
dc.identifier.project | ROD UJ / P | pl |
dc.identifier.uri | http://ruj.uj.edu.pl/xmlui/handle/item/29925 | |
dc.language | eng | pl |
dc.language.container | eng | pl |
dc.rights | Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa | * |
dc.rights.licence | CC-BY | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/legalcode.pl | * |
dc.share.type | otwarte czasopismo | |
dc.subject.en | 1,4-dimethylpyridinium chloride | pl |
dc.subject.en | 1-methylnicotinaimide chloride | pl |
dc.subject.en | angiogenesis | pl |
dc.subject.en | breast cancer | pl |
dc.subject.en | combined therapy | pl |
dc.subject.en | metastasis | pl |
dc.subtype | Article | pl |
dc.title | 1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis | pl |
dc.title.journal | Journal of Experimental & Clinical Cancer Research | pl |
dc.type | JournalArticle | pl |
dspace.entity.type | Publication |
* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.
Views
0
Views per month
Open Access